Huge Unusual Put Options Volume in Merck - Is MRK Stock Overvalued?
Merck & Co., Inc. (MRK) stock experienced a significant uptick in put options trading at a lower strike price of $135.00 as of today, with over 7,000 contracts traded. This unusual activity, comprising nearly 70 times the average put option contracts outstanding, has left analysts wondering if the stock is overvalued. Recent strong Q2 earnings and a 10% spike in the stock price have contributed to the positive movement, with MRK up $14.66 at $149.83 midday trading.
Analysts at Yahoo! Finance have an average price target of $137.73, while Barchart's survey suggests a lower average target of $138.70. However, 14 analysts have a much lower average target of $126.61. EPS estimates for this year have dropped significantly, from $8.98 in 2022 to just $2.75 in 2023. This high P/E ratio of over 54x may be due to one-time acquisition charges, which, when excluded, provide a normalized EPS of $8.68 and forward P/E of 15.67x.
Merck has a history of raising dividends annually, and if the next dividend hike reaches $3.63 (up from $3.24), the current price target would be $123.47. This valuation implies a potential 17.6% decrease below today's price, leading to a revised price range between $123.47 and $188.24, or an average of $155.86, which is only 4% higher than the current price.
Investors may find shorting puts with a breakeven point of $130.09 appealing, as it offers a 19.8% expected return over the next year and a 3% yield over the next three months. However, caution should be exercised, as this strategy could lead to an unrealized loss if MRK's price falls below $130.00.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.